Jefferies Keeps Their Hold Rating on Radius Health (RDUS)


In a report released yesterday, Eun Yang from Jefferies reiterated a Hold rating on Radius Health (NASDAQ: RDUS), with a price target of $25. The company’s shares closed yesterday at $23.36, close to its 52-week low of $22.25.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.0% and a 51.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Alexion Pharmaceuticals, and Amag Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Radius Health with a $41.50 average price target.

See today’s analyst top recommended stocks >>

Based on Radius Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $61.56 million. In comparison, last year the company had a GAAP net loss of $68.44 million.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts